News - Novartis

Filter

Current filters:

Novartis

Popular Filters

1 to 25 of 393 results

$25 million milestone for Incyte on Japanese approval of Jakavi

$25 million milestone for Incyte on Japanese approval of Jakavi

08-07-2014

US biopharma company Incyte says it has earned a $25 million milestone payment from Swiss drug major…

BiotechnologyBusiness FinanceBusiness FinanceFinancialIncyteJakaviJapanMajorMedicineNovartisOncologyRegulationRuxolitinib

Novartis receives fifth Breakthrough Therapy designation with CTL019 for leukemia

Novartis receives fifth Breakthrough Therapy designation with CTL019 for leukemia

08-07-2014

Swiss drug major Novartis has been granted Breakthrough Therapy designation for its leukemia treatment…

CancerCTL019LeukemiaNovartisOncologyPharmaceuticalRefractory acute lymphoblastic leukemiaRegulationUSA

Novartis takes action as former employee is arrested in Japan

Novartis takes action as former employee is arrested in Japan

02-07-2014

Swiss drug major Novartis (NOVN: VX) said yesterday that Novartis Pharma K.K. (NPKK) understands that…

JapanLegalNovartisPharmaceutical

UK’s NICE draft guidance backs Novartis’ Glivec for GISTs

UK’s NICE draft guidance backs Novartis’ Glivec for GISTs

27-06-2014

UK health care watchdog the National Institute for Health and Care Excellence (NICE) has issued new draft…

GlivecNovartisOncologyPharmaceuticalPricingRegulationUK

Novartis subject to Italian investigation over alleged vaccine fraud

Novartis subject to Italian investigation over alleged vaccine fraud

23-06-2014

Swiss drug maker Novartis is the subject of a new investigation by Italian authorities. The company’s…

Health Medical PharmaInfluenzaItalyLegalMedicineNovartisPharmaceuticalPharmacologyVaccines

Novartis outlines aims to be more profitable and increasingly focused

Novartis outlines aims to be more profitable and increasingly focused

19-06-2014

Swiss drug major Novartis has set out its new focused portfolio at the first Meet Novartis Management…

EuropeManagementNovartisOncologyOphthalmicsPharmaceutical

Novartis files for US approval of meningitis B vaccine Bexsero

Novartis files for US approval of meningitis B vaccine Bexsero

17-06-2014

Swiss pharma major Novartis has submitted a Biologic License Application to the US Food and Drug Administration…

BexseroBiotechnologyNovartisRegulationUSAVaccines

FDA licenses Novartis facility to produce cell-culture influenza vaccines

FDA licenses Novartis facility to produce cell-culture influenza vaccines

16-06-2014

The US Food and Drug Administration has licensed Swiss pharma major Novartis’ manufacturing facility…

FlucelvaxNovartisPharmaceuticalProductionRegulationUSAVaccines

Doomed future for Tykerb in breast cancer arena, says analyst

Doomed future for Tykerb in breast cancer arena, says analyst

16-06-2014

The future of Tykerb (lapatinib) in the breast cancer market looks bleak, after the combination of GlaxoSmithKline’s…

BiotechnologyGlaxoSmithKlineMarkets & MarketingNovartisOncologyResearchTykerb

Italian legislation undermines EU regulatory framework by endorsing off-label drug use for economic reasons

Italian legislation undermines EU regulatory framework by endorsing off-label drug use for economic reasons

11-06-2014

The European Federation of Pharmaceutical Industries and Associations says it is concerned about a decision…

AvastinEuropeFinancialItalyNovartisOphthalmicsPharmaceuticalRegulationRoche

Wider use of Novartis’ Gilenya approved in Europe

Wider use of Novartis’ Gilenya approved in Europe

09-06-2014

The European Commission has endorsed the recent Committee for Medicinal Products for Human Use (CHMP)…

EuropeGilenyaNeurologicalNovartisPharmaceuticalRegulation

Avastin could save the USA $29 billion if used instead of Lucentis

Avastin could save the USA $29 billion if used instead of Lucentis

04-06-2014

Using Avastin (bevacizumab) from Swiss drug major Roche instead of Lucentis (ranibizumab) from fellow…

AvastinBevacizumabFinancialLucentisNovartisOphthalmicsPharmaceuticalRocheUSA

EMA/CHMP again rejects Novartis’ serelaxin for AHF

26-05-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has for a second…

Cardio-vascularEuropeNovartisPharmaceuticalReasanzRegulationserelaxin

EMA/CHMP backs Alcon’s Simbrinza for glaucoma

25-05-2014

Swiss drug major Novartis’ eye care division Alcon says that the European Medicines Agency’s Committee…

AlconEuropeNovartisOphthalmicsPharmaceuticalRegulationSimbrinza

Servier inks oncology collaboration with Novartis

20-05-2014

French independent drugmaker Laboratories Servier has signed a strategic global collaboration agreement…

LicensingNovartisOncologyPharmaceuticalServier

Novartis in up to $1 billion deal to acquire ex-US rights to Fovista

Novartis in up to $1 billion deal to acquire ex-US rights to Fovista

20-05-2014

Swiss pharma major Novartis has signed a licensing and commercialization agreement with US biotech firm…

BiotechnologyFovistaLicensingNovartisOphthalmicsOphthotech

US FDA stalls approval of Novartis acute heart failure drug serelaxin, issuing a CRL

US FDA stalls approval of Novartis acute heart failure drug serelaxin, issuing a CRL

16-05-2014

The US Food and Drug Administration has issued a Complete Response Letter regarding the Biologics License…

Cardio-vascularNovartisPharmaceuticalReasanzRegulationserelaxinUSA

Novartis patent settlement on Gleevec with Sun Pharma subsidiary

15-05-2014

The US unit of Swiss drug major Novartis has settled its litigation with the US subsidiary of India’s…

GenericsGleevecNovartisOncologyPatentsSun Pharmaceutical IndustriesUSA

Novartis presents real world data for Lucentis

Novartis presents real world data for Lucentis

09-05-2014

Swiss drug major Novartis has reported data on the eye drug Lucentis (ranibizumab) at the 2014 Association…

AMDEuropeHealthLucentisMajorMedicineNovartisOphthalmicsOphthalmologyPharmaceuticalResearch

Novartis’ Signifor LAR shows superior efficacy in certain acromegaly patients

Novartis’ Signifor LAR shows superior efficacy in certain acromegaly patients

06-05-2014

Swiss drug major Novartis has presented positive results from a pivotal Phase III trial of investigational…

NovartisPharmaceuticalRare diseasesResearchSignifor

1 to 25 of 393 results

Back to top